Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Barclays analyst Gena Wang maintains $Avidity Biosciences(RNA.US)$ with a buy rating, and maintains the target price at $63.According to TipRanks data, the analyst has a success rate of 46.7% and a
Avidity Biosciences to Participate in Upcoming Investor Conferences
Barclays Initiates Avidity Biosciences at Overweight
Barclays Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $63
Barclays analyst Gena Wang initiates coverage on $Avidity Biosciences(RNA.US)$ with a buy rating, and sets the target price at $63.According to TipRanks data, the analyst has a success rate of 46.7%
Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)
Life Science Cares San Diego Scales Partnership With Avidity Biosciences Through Life Science Shares Program
Avidity Biosciences Is Maintained at Outperform by Evercore ISI Group
Avidity Biosciences Price Target Cut to $53.00/Share From $54.00 by Evercore ISI Group
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Lowers Price Target to $53
Avidity Biosciences Analyst Ratings
Evercore Maintains Avidity Biosciences(RNA.US) With Buy Rating, Cuts Target Price to $53
Evercore analyst Gavin Clark-Gartner maintains $Avidity Biosciences(RNA.US)$ with a buy rating, and adjusts the target price from $54 to $53.According to TipRanks data, the analyst has a success
Evercore ISI Trims Price Target on Avidity Biosciences to $53 From $54, Keeps Outperform Rating
Express News | Avidity Biosciences Inc : Evercore ISI Cuts Target Price to $53 From $54
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
These Are the Stocks With the Largest Changes in Short Interest in July - GS
Avidity Biosciences Raises $345.1 Million From Upsized Public Offering
Express News | Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Express News | Avidity Biosciences Inc : BofA Global Research Raises Price Objective to $51 From $45
BofA Securities Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $51
BofA Securities analyst Tazeen Ahmad initiates coverage on $Avidity Biosciences(RNA.US)$ with a buy rating, and sets the target price at $51.According to TipRanks data, the analyst has a success